BiondVax Pharmaceuticals Ltd. announced that all proposed resolutions were approved at the company's Annual General Meeting held on March 24, 2020, including the election of three new directors to the company's Board of Directors, namely, Dr. Yael Margolin, Mr. Adi Raviv, and Mr. Samuel Moed. Mr. Samuel Moed currently serves as Senior Vice President, Corporate Strategy at Bristol Myers Squibb, where for the past six years he has led the strategic direction of the company with close linkage to all of its major businesses, functions and geographies. Dr. Yael Margolin has more than 35 years of experience as senior manager, CEO and board member in venture capital and in the pharmaceutical and biotech industries, leading strategic and business planning, financing, team building, product development and corporate partnerships. Mr. Adi Raviv is a senior financial executive with a career spanning over 30 years. Since April 2016, Mr. Raviv has been a Principal at Capacity Funding LLC, a company providing working capital solutions to small businesses. Concurrently, Ms. Michal Marom Brikman has resigned her position from the Board of Directors.